BRCA Testing in India: Who Should Test, Costs & What Results Mean

• BRCA testing is recommended for specific reasons — a personal or family history of early, bilateral, male, triple-negative, or ovarian cancer — not as a routine health check.
• Test an affected relative first if possible; that makes cheaper, clearer cascade testing possible for the rest of the family.
• In India in 2026, full BRCA1/2 sequencing costs roughly Rs 15,000–40,000, panels Rs 25,000–60,000, and cascade testing for a known mutation only Rs 5,000–10,000.
• A positive result raises risk substantially but does not make cancer inevitable — surveillance, risk-reducing surgery, and chemoprevention all lower that risk.
• Genetic counselling before and after testing is essential, not optional, and good counselling separates high-quality testing from harmful testing.
• India lacks comprehensive genetic anti-discrimination law, so consider insurance and family-communication implications before testing.

BRCA testing is not for everyone. Guidelines from the NCCN (US), ESMO (Europe), and Indian consensus bodies recommend it only for people whose personal or family history points to inherited cancer risk. Population-wide testing of healthy people is not recommended in any major guideline because BRCA mutations are uncommon (around 1 in 300–400 in non-Ashkenazi groups), so untargeted testing finds little and creates a lot of needless worry.

You may be a candidate if you have a personal history of any of the cancers listed below, or a close family history that fits the pattern. The aim is always to discuss these with a genetic counsellor or oncologist before testing, not to self-diagnose.

BRCA mutations occur in every population, but the exact spectrum differs. Certain communities carry recurring "founder" mutations — the best-known being three specific variants in Ashkenazi Jewish populations, where roughly 1 in 40 people carry one. Indian populations have their own founder mutations, increasingly mapped through research at Tata Memorial Hospital, AIIMS, IISc Bengaluru, and national programmes such as IndiGen and the Genomics India initiative.

The practical takeaway: comprehensive sequencing, rather than testing only for a handful of known founder mutations, is the right approach for most Indian women. The Indian mutation spectrum is broader and less fully characterised than the Ashkenazi spectrum.

Multi-gene panel testing — covering BRCA1, BRCA2 and other hereditary cancer genes such as PALB2, ATM, CHEK2, RAD51C, RAD51D, BRIP1, TP53, PTEN, STK11 and CDH1 — is now becoming standard, because inherited breast and ovarian cancer can be caused by any of these and the extra cost is small.

One India-specific caveat: variant-of-uncertain-significance (VUS) results are more common here because reference databases are still dominated by Western populations. A variant called "uncertain" today may be reclassified as benign or harmful as Indian databases grow, so labs often re-evaluate VUS results every 1–3 years.

BRCA and hereditary cancer testing is now widely available in India through three routes — government cancer centres, private hospital chains, and standalone genetic labs — each with different costs.

Government and tertiary cancer centres usually offer the most affordable, counselling-integrated testing. Tata Memorial Hospital (Mumbai), AIIMS Delhi, the Rajiv Gandhi Cancer Institute (Delhi), Adyar Cancer Institute (Chennai), and Kidwai Memorial Institute (Bengaluru) typically charge around Rs 10,000–25,000 for a BRCA1/2 panel including counselling, often partly subsidised for patients with confirmed cancer.

Private hospital chains — Apollo, Manipal, Fortis, Max, HCG, Narayana Health and Medanta — generally charge Rs 15,000–40,000 for BRCA1/2 and Rs 25,000–60,000 for comprehensive panels, usually with in-house counselling.

Standalone labs have driven costs down and widened access: Strand Life Sciences and MedGenome (both Bengaluru-based), Genes2Me, Mapmygenome, Dr Lal PathLabs and Metropolis all offer BRCA and panel testing in similar ranges, often with telemedicine counselling. Cascade testing for a single known family mutation costs only about Rs 5,000–10,000 — far less than full sequencing.

Counselling before and after testing is the single most important factor separating high-quality testing from harmful testing. It is not an optional add-on.

Pre-test counselling covers a detailed 3–4 generation family history, formal risk assessment (using validated tools such as Tyrer-Cuzick or BRCAPRO), an honest explanation of what the test can and cannot reveal, the three possible result types, the insurance and family implications, costs, and informed consent. It usually takes 45–90 minutes and may need more than one visit.

Post-test counselling depends on the result. A positive result triggers a detailed discussion of cancer risks, management options, a family cascade plan, and psychological support. A negative result is explained in the context of family history — it lowers but may not eliminate risk. A VUS is explained as "do not act on this alone" and flagged for periodic review.

India's genetic-counsellor workforce is growing but still limited. Trained counsellors are concentrated at Tata Memorial, AIIMS, RGCI, Apollo, Manipal and the larger labs; the Society of Genetic Counselors of India maintains a directory, and remote counselling now reaches patients outside the metros.

Watch for red flags of low-quality testing: tests ordered with no counselling or risk assessment, results delivered by letter or phone with no explanation, no clear plan after a positive result, testing of children for adult-onset risk, and aggressive direct-to-consumer marketing to people with no real indication.

A positive BRCA1 or BRCA2 result means you have inherited a mutation that substantially raises your lifetime risk of certain cancers — but it does not make cancer inevitable. For BRCA1 carriers, lifetime breast cancer risk is about 60–72% and ovarian cancer risk about 39–44%. For BRCA2 carriers, breast cancer risk is about 55–69% and ovarian cancer risk about 11–17%, plus a modest rise in pancreatic, melanoma and male breast cancer. These are well above the average-risk figures (around 12% lifetime breast and 1.4% lifetime ovarian) — yet many carriers never develop these cancers, especially with surveillance and risk-reducing steps.

There are three broad ways to lower that risk: intensified surveillance, risk-reducing surgery, and chemoprevention. Your choice depends on your age, plans for children, and personal preferences, and should be made with a specialist.

A negative result is only as meaningful as the testing strategy behind it. If you were tested for a specific mutation already found in an affected relative (cascade testing) and you are negative, you genuinely do not carry that family mutation — your risk drops to the population baseline and the intensive carrier measures do not apply. You can return to age-appropriate screening, including mammography from the recommended age and routine cervical screening.

If you were the first person tested in your family (because no affected relative was available) and your BRCA1/2 sequencing is negative, the result is reassuring but not definitive. Your family history may still reflect a mutation in another gene (PALB2, ATM, CHEK2 and others), polygenic risk, shared lifestyle, or chance. Depending on how strong the family history is, you may still need earlier or more intensive screening — discuss your residual risk with a counsellor.

A variant of uncertain significance (VUS) identifies a genetic change whose effect on cancer risk is unclear. A VUS should not drive surgery or intensified surveillance unless your personal and family history would justify that anyway. Most VUS are eventually reclassified as harmless; a minority become pathogenic. Periodic re-evaluation every 1–3 years is standard and often free.

Indian patients see more VUS results than well-studied Western populations, and broader panels (which test more genes) produce more VUS than BRCA1/2 alone. Even so, most experts favour comprehensive panels, because clearly harmful mutations in other genes can be acted on, while a VUS can simply be left alone and reviewed later.

India does not yet have comprehensive genetic anti-discrimination law equivalent to the US GINA Act, so the legal landscape has real gaps worth understanding before you test.

Health insurance discrimination is a genuine concern. Some applications ask about prior genetic testing, and a positive result can affect underwriting — higher premiums, exclusions, or occasionally refusal. The IRDAI has issued limited guidance, but protections remain thin.

Life and disability insurance underwriting may also weigh genetic results. For this reason, some people secure adequate life and disability cover before testing, so it cannot be affected by the result. This is a personal financial decision best discussed with both a financial advisor and a genetic counsellor.

Employment-related genetic discrimination is less prominent in India than in some Western countries, but pre-employment medicals can occasionally raise issues, and the legal framework here is still developing.

Family privacy matters too. You own your result and decide whether to share it, but ethical guidance strongly encourages telling at-risk relatives who could benefit. These conversations are hard; counsellors and cancer centres often provide family-letter templates that explain the finding and recommend testing.

When a harmful BRCA mutation is found, cascade testing of first-degree relatives — siblings, parents, children — turns one diagnosis into prevention across an entire family. Each first-degree relative has a 50% chance of carrying the same mutation. Those who test positive can start surveillance and risk-reducing measures; those who test negative are back at baseline risk.

Cascade testing is simpler and cheaper than the first test, because the lab only looks for the one known variant — typically Rs 5,000–10,000 per relative, and many labs offer reduced family bundles.

Uptake in Indian families is often lower than it should be, for understandable reasons: difficult conversations about a cancer diagnosis, relatives scattered across cities or countries, cumulative cost, low awareness of why testing matters, and cultural reluctance to discuss inherited illness.

BRCA testing matters not only for prevention but for treating cancers that have already developed. For women with breast or ovarian cancer found to carry a BRCA mutation, several treatment options change.

PARP inhibitors (olaparib, niraparib, talazoparib) are targeted drugs that exploit the DNA-repair weakness of BRCA-mutated cells. In ovarian cancer, PARP-inhibitor maintenance after first-line chemotherapy substantially delays recurrence and improves survival in BRCA carriers. In HER2-negative breast cancer, olaparib and talazoparib are approved for metastatic disease, and the OlympiA trial showed olaparib reduces recurrence in early high-risk HER2-negative breast cancer with a germline BRCA mutation.

Costs of these drugs have fallen sharply with Indian generics — olaparib generics now cost roughly Rs 50,000–2 lakh a month against the much higher historical originator price — and PMJAY and private insurers increasingly cover them for approved indications.

BRCA status also shapes surgery and chemotherapy choices. A newly diagnosed carrier may choose bilateral mastectomy over lumpectomy to cut future risk, and BRCA-mutated cancers often respond better to platinum-based chemotherapy. Because of all this, germline BRCA testing is now standard for all ovarian cancers and for breast cancer in the right clinical situations. Read more about early detection and treatment of breast cancer in India.

Because a carrier has a 50% chance of passing the mutation to each child, family planning brings its own decisions. There is no single right answer — the choice is deeply personal.

Preimplantation genetic testing (PGT-M) uses IVF: embryos are tested for the family's specific BRCA mutation and only unaffected embryos are transferred. It is available at major Indian fertility centres at roughly Rs 3–5 lakh per cycle including the IVF and testing. If you are weighing this route, our guides to IVF cost, process and success rates and egg freezing in India are useful background, as is checking ovarian reserve with an AMH test.

Prenatal diagnosis during pregnancy (chorionic villus sampling at 11–13 weeks or amniocentesis at 15–20 weeks) can test a fetus for the mutation, with a small procedure-related miscarriage risk of about 0.5–1%. It raises ethically complex choices that some families accept and others do not — see how these fit into broader prenatal screening in India.

Many carriers choose natural conception and accept the 50% risk, feeling that the next generation's risk is manageable with surveillance. For carriers planning a risk-reducing oophorectomy that will end natural fertility, the usual sequence is to complete childbearing first, then have RRSO at the recommended age, with egg or embryo freezing beforehand if desired. For wider context, see fertility preservation for cancer survivors. Couples may also wish to read about thalassemia carrier screening, another inherited-risk decision common in India.

Genetic risk assessment is most useful before any cancer develops, so it is worth raising these issues early with a doctor rather than waiting. Book a consultation with an oncologist or genetic counsellor if any of the following apply to you or your close family.

• NCCN Clinical Practice Guidelines: Genetic/Familial High-Risk Assessment — Breast, Ovarian, and Pancreatic
• National Cancer Institute (US): BRCA Gene Mutations — Cancer Risk and Genetic Testing
• NHS: Predictive Genetic Tests for Cancer Risk Genes
• Indian Council of Medical Research (ICMR): Consensus Document for Management of Breast Cancer
• ESMO Clinical Practice Guidelines: Hereditary Breast and Ovarian Cancer Syndrome
• OlympiA Trial: Adjuvant Olaparib for Germline BRCA-Mutated Breast Cancer (New England Journal of Medicine)